Implementation of a pharmacist-driven chronic obstructive pulmonary disease transitions of care service at a large academic medical center

IF 1.3 Q4 PHARMACOLOGY & PHARMACY
Maggie M. Lycouras Pharm.D., Nicole E. Cieri-Hutcherson Pharm.D., Brian P. Kersten Pharm.D., Collin M. Clark Pharm.D.
{"title":"Implementation of a pharmacist-driven chronic obstructive pulmonary disease transitions of care service at a large academic medical center","authors":"Maggie M. Lycouras Pharm.D.,&nbsp;Nicole E. Cieri-Hutcherson Pharm.D.,&nbsp;Brian P. Kersten Pharm.D.,&nbsp;Collin M. Clark Pharm.D.","doi":"10.1002/jac5.1933","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States, and one in five COPD hospitalizations result in a readmission within 30 days. Pharmacists have been identified as key members of interdisciplinary teams to improve transitions of care.</p>\n </section>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>The objective of this study was to develop, implement, and evaluate outcomes for a pharmacist-driven COPD transitions of care bundle at an academic medical center.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A COPD care bundle was implemented for patients presenting with a COPD exacerbation from December 1, 2021 to February 28, 2022. A historical control group was created from patients who were discharged between December 1, 2020 and February 28, 2021. Patient characteristics, pharmacist-driven interventions, and time required for the intervention were assessed descriptively. Inhaler technique was assessed before and after pharmacist education utilizing standardized rubrics. The percentage change in inhaler scores was assessed with a Wilcoxon signed-rank test. Readmission outcomes were analyzed using a chi-squared test.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 30 patients in the intervention group and 46 in the control group. There were 104 interventions requiring provider collaboration, of which 84 (81%) were accepted. A median (interquartile range, IQR) of 46 (37–55) min was spent per patient in the intervention group. At baseline, patients scored a median of 84.6% (75–100) of steps correctly across all inhaler device types. After pharmacist education, patient scores increased to a median of 100% [92.3–100] (<i>p</i> &lt; 0.0001). There were eight (26.7%) 30-day all-cause readmission rates in the intervention group and 15 (32.6%) in the control group (<i>p</i> = 0.58).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Most pharmacist recommendations were accepted by providers. Medication education led to improved understanding of inhaler technique, but there was no difference in 30-day readmission rates. Further development of this service is warranted based on these findings.</p>\n </section>\n </div>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jac5.1933","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality in the United States, and one in five COPD hospitalizations result in a readmission within 30 days. Pharmacists have been identified as key members of interdisciplinary teams to improve transitions of care.

Objective

The objective of this study was to develop, implement, and evaluate outcomes for a pharmacist-driven COPD transitions of care bundle at an academic medical center.

Methods

A COPD care bundle was implemented for patients presenting with a COPD exacerbation from December 1, 2021 to February 28, 2022. A historical control group was created from patients who were discharged between December 1, 2020 and February 28, 2021. Patient characteristics, pharmacist-driven interventions, and time required for the intervention were assessed descriptively. Inhaler technique was assessed before and after pharmacist education utilizing standardized rubrics. The percentage change in inhaler scores was assessed with a Wilcoxon signed-rank test. Readmission outcomes were analyzed using a chi-squared test.

Results

There were 30 patients in the intervention group and 46 in the control group. There were 104 interventions requiring provider collaboration, of which 84 (81%) were accepted. A median (interquartile range, IQR) of 46 (37–55) min was spent per patient in the intervention group. At baseline, patients scored a median of 84.6% (75–100) of steps correctly across all inhaler device types. After pharmacist education, patient scores increased to a median of 100% [92.3–100] (p < 0.0001). There were eight (26.7%) 30-day all-cause readmission rates in the intervention group and 15 (32.6%) in the control group (p = 0.58).

Conclusion

Most pharmacist recommendations were accepted by providers. Medication education led to improved understanding of inhaler technique, but there was no difference in 30-day readmission rates. Further development of this service is warranted based on these findings.

在一家大型学术医疗中心实施由药剂师驱动的慢性阻塞性肺病过渡护理服务
慢性阻塞性肺病(COPD)是美国发病率和死亡率的主要原因,每五例慢性阻塞性肺病住院患者中就有一人在 30 天内再次入院。本研究的目的是在一家学术医疗中心开发、实施并评估由药剂师驱动的慢性阻塞性肺疾病转归护理捆绑疗法的效果。从 2021 年 12 月 1 日至 2022 年 2 月 28 日,对出现慢性阻塞性肺疾病加重的患者实施了慢性阻塞性肺疾病护理捆绑疗法。从 2020 年 12 月 1 日至 2021 年 2 月 28 日期间出院的患者组成历史对照组。对患者特征、药剂师主导的干预措施和干预所需时间进行了描述性评估。在药剂师教育前后,使用标准化评分标准对吸入器技术进行了评估。吸入器评分的百分比变化采用 Wilcoxon 符号秩检验进行评估。干预组有 30 名患者,对照组有 46 名患者。需要医疗服务提供者合作的干预措施有 104 项,其中 84 项(81%)被接受。干预组每位患者的干预时间中位数为 46(37-55)分钟。基线时,患者对所有吸入器设备类型的正确步骤的评分中位数为 84.6%(75-100 分)。经过药剂师教育后,患者得分的中位数提高到 100%[92.3-100](P < 0.0001)。干预组 30 天内全因再入院率为 8 例(26.7%),对照组为 15 例(32.6%)(p = 0.58)。用药教育提高了患者对吸入器使用技巧的了解,但 30 天再入院率没有差异。基于这些研究结果,有必要进一步发展这项服务。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.70
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信